You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ROS1 Gene Rearrangements

Showing 1 - 25 of 6,159
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Protein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Tumors Trial in Guangzhou (JYP0322)

Recruiting
  • Protein Kinase Inhibitors
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Nov 9, 2023

NSCLC Trial in Worldwide (Entrectinib, Crizotinib)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Barretos, SP, Brazil
  • +66 more
Jan 27, 2023

Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • +4 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory

Withdrawn
  • Advanced Malignant Neoplasm
  • +10 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer Trial in France (Blood and tumor samples)

Recruiting
  • Soft Tissue Sarcoma
  • +2 more
  • Blood and tumor samples
  • Clermont-Ferrand, France
  • +9 more
Dec 8, 2021

Breast Cancer, Cholangiocarcinoma, Colorectal Cancer Trial in Worldwide (Entrectinib)

Recruiting
  • Breast Cancer
  • +15 more
  • Goodyear, Arizona
  • +146 more
Aug 24, 2022

Advanced Solid Tumor, Metastatic Solid Tumor Trial in Canton (TPX-0005, Metformin Hydrochloride, Digoxin)

Recruiting
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Canton, Ohio
    Gabrail Cancer Research Center
Apr 25, 2023

Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic NSCLC Trial in Beijing (XZP-5955 tablets)

Recruiting
  • Locally Advanced or Metastatic Solid Tumors
  • Locally Advanced or Metastatic Non-small Cell Lung Cancer
  • XZP-5955 tablets
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
May 17, 2022

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene

Recruiting
  • Non Small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 9, 2022

    Advanced Solid Malignant Tumors Trial in Fukuoka, Osaka, Tokyo (DS-6051b)

    Active, not recruiting
    • Advanced Solid Malignant Tumors
    • Fukuoka, Japan
    • +2 more
    Jan 18, 2022

    Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)

    Recruiting
    • Nsclc
    • +5 more
    • Hong Kong, Hong Kong
      Queen Mary Hospital
    Nov 25, 2021

    Solid Tumor, Haematological Malignancy, Malignancy Trial in United Kingdom (Entrectinib)

    Recruiting
    • Solid Tumor
    • +10 more
    • Belfast, United Kingdom
    • +25 more
    Mar 14, 2023

    Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI

    Recruiting
    • Non-Small Cell Carcinoma of Lung, TNM Stage 4
    • +5 more
      • Aurora, Colorado
        University of Colorado, Cancer Center
      Nov 3, 2021

      Activating ALK Gene Mutation Negative, Activating EGFR Gene Mutation Negative, Activating ROS1 Gene Mutation Negative Trial in

      Completed
      • Activating ALK Gene Mutation Negative
      • +7 more
      • Counseling
      • +2 more
      • Philadelphia, Pennsylvania
        Sidney Kimmel Cancer Center at Thomas Jefferson University
      Sep 7, 2022

      Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Trial in Shanghai (SIM1803-1A)

      Recruiting
      • Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion
      • Shanghai, China
        Shanghai Chest Hospital
      Jan 11, 2021

      Locally Advanced Solid Tumors, Metastatic Solid Tumors Trial in Worldwide (Oral repotrectinib (TPX-0005))

      Recruiting
      • Locally Advanced Solid Tumors
      • Metastatic Solid Tumors
      • Oral repotrectinib (TPX-0005)
      • Yuma, Arizona
      • +175 more
      Jan 25, 2023

      Mediastinal Lymphadenopathy, Hilar Lymphadenopathy, Lymphoma Trial in Ancona (No suction EBUS-TBNA, Passive suction through

      Not yet recruiting
      • Mediastinal Lymphadenopathy
      • +9 more
      • No suction EBUS-TBNA
      • +2 more
      • Ancona, Italy
        Pulmonary Diseases Unit, Department of Immunoallergic and Respir
      May 25, 2022

      Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements Trial in Worldwide (TAS-120, Cisplatin/Gemcitabine)

      Active, not recruiting
      • Advanced Cholangiocarcinoma
      • FGFR2 Gene Rearrangements
      • Albuquerque, New Mexico
      • +100 more
      Feb 1, 2023

      Non Small Cell Lung Cancer Trial in Shanghai (AB-106)

      Recruiting
      • Non Small Cell Lung Cancer
      • Shanghai, Shanghai, China
        Shanghai Pulmonary Hospital
      Jun 17, 2021

      NSCLC, Crizotinib, ALK Gene Rearrangement or ROS1 Gene Rearrangement Trial in France

      Completed
      • NSCLC
      • +2 more
        • Aix en Provence, France
        • +25 more
        Sep 24, 2021

        Nonsmall Cell Lung Cancer Trial in Goyang-Si (Lorlatinib)

        Recruiting
        • Nonsmall Cell Lung Cancer
        • Goyang-Si, Gyeonggi-do, Korea, Republic of
          National Cancer Center
        Apr 4, 2022

        NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation Trial in France (Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab,

        Recruiting
        • NSCLC Stage IIIB
        • +4 more
        • Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
        • Carboplatin + Pemetrexed + Atezolizumab
        • Angers, France
        • +30 more
        Jun 7, 2021

        Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement Trial in Boston (Lorlatinib, Crizotinib,

        Recruiting
        • Lung Cancer
        • +6 more
        • Boston, Massachusetts
        • +1 more
        Mar 7, 2021

        NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

        Not yet recruiting
        • Non-small Cell Lung Cancer (NSCLC)
        • MK-2870
        • +2 more
        • (no location specified)
        Oct 3, 2023